STOCK MARKET BSE NSE

Ebola outbreak: Death toll in DR Congo now at 61

The health ministry's General Directorate for Combatting Disease said 103 cases of Ebola had been recorded in the eastern DRC as of August 22, 76 of which had been confirmed by laboratory tests.

Published: 23rd August 2018 07:03 PM  |   Last Updated: 23rd August 2018 07:03 PM   |  A+A-

A family member of a deceased, unconfirmed Ebola patient, reacts inside an Ebola Treatment Centre run by The Alliance for International Medical Action. (Photo | AFP)

By AFP

BENI: Sixty-one people have died in the latest outbreak of Ebola in the Democratic Republic of Congo (DRC), the authorities said, adding that four novel drugs had been added to the roster of treatments.

The health ministry's General Directorate for Combatting Disease said 103 cases of Ebola had been recorded in the eastern DRC as of August 22, 76 of which had been confirmed by laboratory tests.

Of the 103 cases, there were 61 deaths, 34 of which been confirmed by lab tests, while 27 others were considered "probable" cases of Ebola.

ALSO READ | A timeline of major Ebola outbreaks

The outbreak began on August 1 in Mangina in North Kivu province, and cases have been reported in neighbouring Ituri province.

It is the 10th outbreak to strike the DRC since 1976, when Ebola was first identified and named after a river in the north of the country.

The health ministry added that "four additional experimental therapeutic molecules" had been approved by its ethics committee for treating infected patients.

Their laboratory names are ZMapp; Remdesivir; Favipiravir; and Regn3450 – 3471 – 3479.

Red Cross workers disinfect a coffin in DR Congo. (Photo | AFP)

The drugs -- which have not been licensed but undergone safety trials -- add to a prototype treatment called mAb114, whose use was announced on August 14.

The first therapeutic drug against the virus to be used in an active Ebola epidemic in the DRC, mAB114, has so far been given to 10 patients "who are responding positively," the ministry said. 

Developed in the United States, the prototype drug is a so-called single monoclonal antibody -- a protein that binds on to a specific target of the virus and triggers the body's immune system to destroy the invader.

The experimental treatments are being used alongside an unlicensed vaccine called rVSV-ZEBOV, which was shown to be safe and effective in previous trials in an Ebola epidemic in West Africa.

ALSO READ | Ebola death toll in DR Congo rises to 55 

Immunisation with rVSV-ZEBOV has been given to 2,179 front-line health workers, the ministry said.

The WHO has expressed concern that the violence in the province Kivu -- entailing militias who often fight for control of resources, including a notorious Ugandan rebel force called the Allied Democratic Forces (ADF) -- could hamper the fight against rolling back the disease.

The outbreak in eastern DRC was declared a week after WHO and the government hailed the end of a flareup in northwestern Equateur province, at the other end of the vast country, which killed 33 people.  

The government has earmarked $43 million (37 million euros) to fight the latest scare.

Medical staff check each others protective suits before entering the isolation unit at a hospital.
(Photo | AFP)

Ebola is a highly contagious haemorrhagic fever caused by a virus which is believed to have a natural home in species of tropical bats.

ALSO READ | Congo's health ministry says Ebola spreads to second province

It causes serious illness including vomiting, diarrhoea and in some cases internal and external bleeding. It is often fatal.

In the worst Ebola epidemic, the disease struck the West African states of Guinea, Liberia and Sierra Leone in 2013-15, killing more than 11,300 people.

Stay up to date on all the latest World news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp